药明生物(02269)发盈喜 预计2025年度归属于公司权益股东的利润同比增长约46.3%至49.08亿元

Core Viewpoint - WuXi Biologics (02269) anticipates a revenue growth of approximately 16.7% year-on-year, reaching RMB 21.79 billion for the fiscal year ending December 31, 2025, alongside significant increases in profit margins and adjusted net profit [1][2] Group 1: Financial Projections - The company expects its gross profit margin to improve by about 5 percentage points to 46.0% [1] - Adjusted gross profit is projected to rise to approximately RMB 10.64 billion, reflecting a year-on-year growth of about 25.5% [1] - Profit attributable to equity shareholders is forecasted to increase by approximately 45.3% to RMB 5.73 billion, while net profit is expected to grow by about 46.3% to RMB 4.91 billion [1] - Adjusted net profit, after accounting for share-based compensation, foreign exchange gains and losses, equity investments, asset sales, restructuring gains and related one-off costs, is anticipated to grow by about 22.0% to RMB 6.59 billion [1] Group 2: Growth Drivers - The growth is primarily driven by the successful execution of the "Follow and Win Molecule" strategy, leading to increased revenue through advanced technology platforms and industry-best project delivery times [2] - The company has expanded its service offerings in the biopharmaceutical sector, including research and discovery services, pre-IND development services, and clinical and commercial production services, leveraging rapidly developing technology platforms such as bispecific antibodies and ADCs [2] - Revenue growth from research services has been generated through multiple advanced technologies [2] - The utilization of existing and new production capacities, including ramp-up at European production facilities, has contributed to growth [2] - Cost savings and efficiency improvements have been achieved through the WuXi Biologics Lean Operations Management System (WBS) and digital solutions [2] - Investment income has been obtained through the company's investment portfolio [2]